RESULTS
ONCOLOGY
Between January 2011 and February 2013, 195 patients were randomly allocated to the S + XP arm (Baseline patient characteristics.Abbreviations: ECOG, Eastern Cooperative Oncology Group; S, sorafenib; XP, capecitabine and cisplatin.The trial database was locked in November 2013 for the final analysis, according to predetermined criteria.